Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AngloGold Ashanti Limited (AU) vs Sanofi SA (SNY) Price & Performance

AngloGold Ashanti LimitedTrade

Price performance (Past 24H)

Key statistics

AngloGold Ashanti Limited vs Sanofi SA — how do they compare? AngloGold Ashanti Limited trades at $98.02 (market cap $49.28B), while Sanofi SA trades at $43.58 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.1× AngloGold Ashanti Limited's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

AUSNY
Market Cap
$49.28B$104.30B
Sector
Basic MaterialsHealth
52-Week High
$128.26$52.34
52-Week Low
$52.15$41.33
Enterprise Value
$48.29B$124.19B
Dividend Yield
4.64%5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AngloGold Ashanti Limited

AngloGold Ashanti (AU) trades at $98.20, up 0.98% today, near its 52-week high. The stock shows strong fundamental momentum with revenue surging to $9.89B in 2025 and net income reaching $2.64B. Analysts maintain a bullish consensus with a $120.33 price target, supported by robust cash flow and a $2B buyback program. Technical indicators are mixed, with moving averages bullish but RSI levels suggesting overbought conditions. Recent news highlights operational strength and institutional accumulation.

Outlook remains positive driven by gold price strength and production growth, but risks include commodity volatility and operational execution. The stock offers value with a P/E of 13.06 and high profitability margins, though overbought technicals may prompt near-term consolidation. Investor sentiment is favorable, but macroeconomic factors could impact performance.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AngloGold Ashanti Limited

Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.

Read more on AU

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY